Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in Science Advances detailing the company’s CRISPR-based Cellgorithm technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.
Programmable CRISPR platform can reduce stem cell differentiation from months to weeks
